IDEAYA Biosciences, Inc.
About IDEAYA Biosciences, Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $218.7M
- Net income
- -$113.7M
- Total assets
- $1.1B
- Market cap
- $2.5B
- Operating margin
- -72.8%
- Net margin
- -52.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $218.7M
- Operating expenses
- $378.0M
- Operating income
- -$159.3M
- Income tax
- $0
- Net income
- -$113.7M
- EPS (basic)
- $-1.28
- EPS (diluted)
- $-1.28
Balance sheet
- Total assets
- $1.1B
- Current assets
- $666.7M
- Total liabilities
- $86.4M
- Current liabilities
- $58.8M
- Shareholders’ equity
- $1.0B
Cash flow
- Operating cash flow
- -$71.1M
- Investing cash flow
- $70.0M
- Financing cash flow
- $29.8M
- Net cash flow
- $28.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.5B
- EPS (diluted)
- $-1.28
- Shares outstanding
- 79.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 23, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $113.7M in FY2025.
- Revenue grew 683% from FY2021 to FY2025.
- Trading 17% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review IDEAYA Biosciences, Inc..
Write a review
News about IDEAYA Biosciences, Inc.
News & sentiment via Polygon.io
